Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.

Related Articles

Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.

Cutis. 2017 Feb;99(2):E30-E34

Authors: Eshagh K, Romero LS, So JK, Zhao XF

Abstract
Various infections, autoimmune diseases, medications, and total-body irradiation are known factors associated with CD4 lymphopenia, defined as a CD4 T-cell count below 300 cells/mL or less than 20% of total lymphocytes. We report a rare case of a patient with cutaneous T-cell lymphoma (CTCL) who developed profound CD4 lymphopenia in the setting of long-term bexarotene therapy. Bexarotene is a third-generation retinoid that inhibits epithelial cell proliferation and is approved for treatment of advanced CTCL (stages IIB-IVB) in adult patients who have failed at least 1 prior systemic therapy. This case illustrates the importance of surveillance for CD4 leukopenia in patients on long-term bexarotene therapy with routine complete blood cell counts (CBC) and T-cell counts as well as consideration of rotating patients off bexarotene therapy even in those who derive continuous benefit.

PMID: 28319634 [PubMed - indexed for MEDLINE]

from #ENT-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2mL175U